Peripheral retinal neovascularization in a patient with pilocytic astrocytoma

We described a case of papilledema complicated by peripheral retinal vessels in a 12-year-old boy affected by cerebellar astrocytoma. Opportunity to treat with photocoagulation or intravitreal anti-VEGF (vascular endothelial growth factor) injections was discussed with the parents and no treatment was done. After 5 years from surgery, retinal neovascularization was stable without vitreal hemorrhages or retinal complications, more specifically fibrosis of the neovessels increased and leakage phenomena were reduced at the fluorescein angiography. To our knowledge, this is a unique case of papilledema complicated by peripheral retinal vessels in a patient affected by cerebellar astrocytoma.

Download Full-text

Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins.

Proceedings of the National Academy of Sciences ◽

10.1073/pnas.92.23.10457 ◽

1995 ◽

Vol 92 (23) ◽

pp. 10457-10461 ◽

Cited By ~ 779

Author(s):

L. P. Aiello ◽

E. A. Pierce ◽

E. D. Foley ◽

H. Takagi ◽

H. Chen ◽

...

Keyword(s):

Vascular Endothelial Growth Factor ◽

Growth Factor ◽

Retinal Neovascularization ◽

Chimeric Proteins ◽

Vegf Receptor ◽

Vascular Endothelial ◽

Endothelial Growth Factor

Download Full-text

MicroRNA‐9 inhibits retinal neovascularization in rats with diabetic retinopathy by targeting vascular endothelial growth factor A

Journal of Cellular Biochemistry ◽

10.1002/jcb.28081 ◽

2018 ◽

Vol 120 (5) ◽

pp. 8032-8043 ◽

Cited By ~ 2

Author(s):

Wen‐Lan Liu

Keyword(s):

Vascular Endothelial Growth Factor ◽

Diabetic Retinopathy ◽

Growth Factor ◽

Retinal Neovascularization ◽

Vascular Endothelial ◽

Endothelial Growth Factor

Download Full-text

The Interaction between the Renin-Angiotensin System and Vascular Endothelial Growth Factor in the Pathogenesis of Retinal Neovascularization in Diabetes

Journal of Vascular Research ◽

10.1159/000051088 ◽

2001 ◽

Vol 38 (6) ◽

pp. 527-535 ◽

Cited By ~ 13

Author(s):

Jennifer L. Wilkinson-Berka ◽

Darren J. Kelly ◽

Richard E. Gilbert

Keyword(s):

Vascular Endothelial Growth Factor ◽

Growth Factor ◽

Renin Angiotensin System ◽

Retinal Neovascularization ◽

Vascular Endothelial ◽

Angiotensin System ◽

Renin Angiotensin ◽

Endothelial Growth Factor

Download Full-text

Delayed Laser photocoagulation following intravitreal anti–vascular endothelial growth factor injection allows immature retinal vessels to regrow without recurrence of retinopathy of prematurity

10.21203/rs.2.19459/v1 ◽

2019 ◽

Author(s):

Ki Yup Nam ◽

Ji Eun Lee ◽

Joo Eun Lee ◽

Hyun Wong Kim ◽

Sang Joon Lee

Keyword(s):

Vascular Endothelial Growth Factor ◽

Growth Factor ◽

Laser Photocoagulation ◽

Retinal Vessel ◽

Disease Recurrence ◽

Retinal Vessels ◽

Vascular Endothelial ◽

Zone Ii ◽

Vessel Development ◽

Endothelial Growth Factor

Abstract Purpose: The effects of delayed laser photocoagulation (LP) for ROP patients who received intravitreal anti–vascular endothelial growth factor injections (IVAs) on peripheral vascularization and disease recurrence in ROP patients. Methods: A total of 26 consecutive infant eyes of 14 patients who received IVA treatments were retrospectively investigated. The patients were divided into two groups depending on the initial treatment as follows: IVA group and prompt LP group. Recurrence of ROP, growth of the retinal vessels, and associated complications were evaluated. Results: There were 16 eyes in the IVA group and 10 eyes in the LP group. In the IVA group, delayed LP was performed in six eyes due to recurrences of ROP. In 16 eyes of the IVA group, the retinal vessels grew upto Zone III in eyes received IVA only. Among the IVA groups, Delayed LP was needed in six eyes due to ROP recurrence following IVA. Delayed LP was performed average 7~8 weeks after IVA, which could give the immature neurovascular tissues time to continue vascular development upto Zone II without further ROP recurrence. However, the prompt LP group did not show vessel development beyond the laser scar. Conclusions: Delayed LP following IVA might provide a chance for retinal vessel development in the immature retina to continue without unexpected ROP recurrences.

Download Full-text

Evogliptin, a dipeptidyl peptidase-4 inhibitor, attenuates pathological retinal angiogenesis by suppressing vascular endothelial growth factor-induced Arf6 activation

Experimental & Molecular Medicine ◽

10.1038/s12276-020-00512-8 ◽

2020 ◽

Vol 52 (10) ◽

pp. 1744-1753

Author(s):

Songyi Seo ◽

Mi-Kyung Kim ◽

Ryul-I Kim ◽

Yeongju Yeo ◽

Koung Li Kim ◽

...

Keyword(s):

Vascular Endothelial Growth Factor ◽

Diabetic Retinopathy ◽

Growth Factor ◽

Dipeptidyl Peptidase ◽

Inhibitory Effect ◽

Retinal Neovascularization ◽

Vegf Receptor ◽

Vascular Endothelial ◽

Dipeptidyl Peptidase 4 ◽

Endothelial Growth Factor

Abstract Dipeptidyl peptidase-4 (DPP-4) inhibitors are used for the treatment of type 2 diabetes mellitus (DM). Recent studies have shown that beyond their effect in lowing glucose, DPP-4 inhibitors mitigate DM-related microvascular complications, such as diabetic retinopathy. However, the mechanism by which pathological retinal neovascularization, a major clinical manifestation of diabetic retinopathy, is inhibited is unclear. This study sought to examine the effects of evogliptin, a potent DPP-4 inhibitor, on pathological retinal neovascularization in mice and elucidate the mechanism by which evogliptin inhibits angiogenesis mediated by vascular endothelial growth factor (VEGF), a key factor in the vascular pathogenesis of proliferative diabetic retinopathy (PDR). In a murine model of PDR, an intravitreal injection of evogliptin significantly suppressed aberrant retinal neovascularization. In human endothelial cells, evogliptin reduced VEGF-induced angiogenesis. Western blot analysis showed that evogliptin inhibited the phosphorylation of signaling molecules associated with VEGF-induced cell adhesion and migration. Moreover, evogliptin substantially inhibited the VEGF-induced activation of adenosine 5′-diphosphate ribosylation factor 6 (Arf6), a small guanosine 5′-triphosphatase (GTPase) that regulates VEGF receptor 2 signal transduction. Direct activation of Arf6 using a chemical inhibitor of Arf-directed GTPase-activating protein completely abrogated the inhibitory effect of evogliptin on VEGF-induced activation of the angiogenic signaling pathway, which suggests that evogliptin suppresses VEGF-induced angiogenesis by blocking Arf6 activation. Our results provide insights into the molecular mechanism of the direct inhibitory effect of the DPP-4 inhibitor evogliptin on pathological retinal neovascularization. In addition to its glucose-lowering effect, the antiangiogenic effect of evogliptin could also render it beneficial for individuals with PDR.

Download Full-text